CN111973587B - 槲皮素在制备抗草鱼呼肠孤病毒药物中的用途 - Google Patents
槲皮素在制备抗草鱼呼肠孤病毒药物中的用途 Download PDFInfo
- Publication number
- CN111973587B CN111973587B CN202010965543.2A CN202010965543A CN111973587B CN 111973587 B CN111973587 B CN 111973587B CN 202010965543 A CN202010965543 A CN 202010965543A CN 111973587 B CN111973587 B CN 111973587B
- Authority
- CN
- China
- Prior art keywords
- quercetin
- grass carp
- gcrv
- medicine
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 title claims abstract description 88
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 title claims abstract description 44
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 title claims abstract description 44
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 235000005875 quercetin Nutrition 0.000 title claims abstract description 44
- 229960001285 quercetin Drugs 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 241000252233 Cyprinus carpio Species 0.000 title claims description 11
- 241000702263 Reovirus sp. Species 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 241000609060 Grass carp reovirus Species 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 14
- 238000009360 aquaculture Methods 0.000 abstract description 8
- 244000144974 aquaculture Species 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000007613 environmental effect Effects 0.000 abstract description 4
- 241000353204 Girella Species 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 8
- 241000252230 Ctenopharyngodon idella Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241000238557 Decapoda Species 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000002155 anti-virotic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- -1 flavonoid compound Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 235000007519 Chimonanthus praecox Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000219428 Fagaceae Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 240000001359 Origanum dictamnus Species 0.000 description 1
- 235000015987 Origanum dictamnus Nutrition 0.000 description 1
- 235000004383 Origanum vulgare subsp. vulgare Nutrition 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了槲皮素在制备抗草鱼呼肠孤病毒药物中的用途，槲皮素作为抗病毒活性成分用于制备抗草鱼呼肠孤病毒的药物，其应用剂量为0.1‑100μM/L。本发明发现槲皮素可以抑制GCRV病毒，且通过细胞水平实验证明槲皮素抗GCRV病毒效果良好，因其原料成本低廉，绿色安全，符合当前水产养殖绿色鱼药对安全、环保的要求，作为抗GCRV的水产养殖用绿色药物可满足抗GCRV病毒要求的同时，降低成本，便于大规模应用。
Description
技术领域
本发明属于水产养殖药物领域，具体涉及槲皮素在制备抗草鱼呼肠孤病毒药物中的用途。
背景技术
我国是水产养殖大国，草鱼(Ctenopharyngodon Idellus)是我国的主要经济养殖鱼类之一，草鱼由于饲料来源广、生长速度快及经济价值高而广受养殖人员的喜爱，养殖范围广且规模大，但草鱼抗病能力差，各个阶段都易受到病害感染，常见疾病有草鱼肠炎病、赤皮病、烂鳃病和病毒性出血病。由草鱼呼肠孤病毒(Grass Carp Reovirus，GCRV)引起的草鱼出血病是草鱼养殖中较为严重的传染病之一，发现的草鱼呼肠孤病毒株按照是否具有最外层吸附蛋白来分类主要有具有吸附蛋白的GCRV毒株如GCRV104株和GCRV106株，以及不具有吸附蛋白的GCRV毒株如GCRV-873株和GCRV-JX01株。目前，市场上主要采用草鱼呼肠孤病毒灭活疫苗和减毒活疫苗进行该病的防控，但是通过注射途径给鱼类使用疫苗费时费力，且注射过程中对鱼体有一定的损伤，因为鱼类免疫学的相关研究相较于哺乳动物还比较落后，导致鱼类疫苗对宿主的免疫保护期和保护率等指标仍然处于探索研究过程中，在中国市场上仅有一个针对不具有外衣壳蛋白基因型GCRV毒株的疫苗获得兽药证书，仍需要广泛开发针对不同基因型的广谱、高效、环境友好且价格低廉、稳定性好的病毒性草鱼出血病防控药物。
槲皮素(Quercetin)，是一种广泛存在于自然界的天然黄酮类化合物，已经发现它具有多重生物活性，如抗氧化、抗病毒、抗炎作用，在细胞和动物实验中可以用来治疗肝、心、脾、肺、肾、骨科疾病、神经系统疾病等，具有抗氧化、抗炎、抗病毒、抗肿瘤、降糖、降脂、免疫调节等生物活性和广泛的药理学作用，对治疗细菌感染、病毒感染、肿瘤、糖尿病、高血脂和免疫系统疾病均具有十分重要的临床意义，但是在水产养殖抗病毒方面的研究十分有限，专利申请(公开号：CN 107668327 A)公开了槲皮素金属螯合物在动物饲料添加剂的应用，槲皮素和金属离子结合具有很好的抗应激、抗氧化、消炎、抗菌作用，对动物的生长发育、治疗动物腹泻具有很好的作用。专利申请(公开号：CN 106260742 A)公开了抗氧化剂在消减动物体内真菌毒素残留中的应用，通过在对虾饲料中添加槲皮素、芦丁或者茶多酚诱导剂来诱导染毒对虾肠道内源解毒酶的活性来加速对虾体内毒素的代谢，降低或清除毒素的残留，确保对虾食品安全，但尚未发现利用槲皮素防控水生动物病毒的研究报道。
发明内容
本发明的主要目的是，提供槲皮素在制备抗草鱼呼肠孤病毒药物中的用途。
为实现上述发明目的，采用的技术方案是：槲皮素在制备抗草鱼呼肠孤病毒药物中的用途。
根据本发明的一些实施方案，所述抗草鱼呼肠孤病毒药物以槲皮素为活性成分，且所述槲皮素的应用剂量为0.1-100μM/L，优选为25-50μM/L。
根据本发明的一些实施方案，所述抗草鱼呼肠孤病毒药物还包括药学上可接受的辅料。
根据本发明的一些实施方案，所述抗草鱼呼肠孤病毒药物的剂型包括片剂、粉剂、颗粒剂、胶囊或缓释剂。
根据本发明的一些实施方案，所述抗草鱼呼肠孤病毒药物的给药方式为拌饲投喂。
与现有技术相比，本发明首次发现槲皮素可以抑制GCRV病毒，且通过细胞水平实验发现槲皮素抗GCRV病毒效果良好，因其原料成本低廉，绿色安全且效果良好，符合当前水产养殖绿色鱼药对安全、环保的要求，将其作为抗GCRV的水产养殖用绿色药物，为水产防治GCRV提供新的途径。
附图说明
图1是槲皮素对CIK细胞的安全浓度检测。
图2是不同浓度槲皮素对两种类型GCRV的抑制效果，其中，(a)为GCRV104毒株，(b)为JX01毒株。
图3是50μM浓度的槲皮素对GCRV的抗病毒活性影响。
具体实施方式
下面结合附图和实施例对本发明的实施方案进行详细描述，但是本领域技术人员将会理解，下列实施例仅用于说明本发明，而不应视为限定本发明的范围。实施例中未注明具体条件者，按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者，均为可以通过市购获得的常规产品。
槲皮素，分子式为
槲皮素作为一种广泛存在于自然界的天然黄酮类化合物，研究发现其具有多重生物活性，如抗氧化、抗病毒、抗炎作用，在细胞和动物实验中可以用来治疗肝、心、脾、肺、肾、骨科疾病、神经系统疾病等，具有抗氧化、抗炎、抗病毒、抗肿瘤、降糖、降脂、免疫调节等生物活性和广泛的药理学作用，临床上可望用于治疗细菌感染、病毒感染、肿瘤、糖尿病、高血脂和免疫系统疾病，如用于支气管炎及多痰炎症，辅助治疗冠心病及高血压等。可以通过以下任一生产方法得到：
(1)将山毛榉科的栎属植物的树皮磨碎成粉末，用热食盐水洗涤，用稀氨水抽提后，用稀硫酸中和。煮沸滤液，析出结晶而得；
(2)百合科植物洋葱等用95％乙醇提取；
(3)芸香苷(芦丁)提取物及槲皮苷、异槲皮苷、茴香苷、金丝桃苷、槲皮黄苷、腊梅苷等经芸香苷分解酶或酸性水溶液水解而得。
下面实施例中以草鱼肾脏细胞系CIK细胞验证槲皮素用于抗GCRV病毒的效果，采用的GCRV病毒为GCRV104毒株和GCRV-JX01株。
实施例1 槲皮素对CIK细胞的安全浓度检测
在草鱼肾脏细胞系CIK细胞上进行槲皮素安全浓度的检测，设置0-400μM的浓度梯度的槲皮素处理CIK细胞96h，收集每个处理组的所有细胞，使用MuseTM检测各个处理组的细胞活力，结果如图1所示。
由图可知，槲皮素在小于100μM浓度范围内对CIK细胞活性影响较小，细胞活性与NC对照组无明显差异(均为94％左右)，浓度大于100μM时对细胞活力影响较大，细胞活力小于90％。
实施例2 安全浓度内GCRV的抗病毒活性检测
将CIK细胞传到6孔板，待细胞基本长满整个孔板时加入病毒，孵育1h后去除上清，分别加入0、25、50、100μM的槲皮素，检测感染72h后各个浓度的病毒滴度，结果如图2所示。
由图可知，在安全浓度范围内槲皮素可以有效拮抗GCRV，并且呈现剂量依赖性。
实施例3 50μM槲皮素对GCRV不同时间点的抗病毒活性
将CIK细胞传到6孔板，待细胞基本长满整个孔板时加入病毒，孵育1h后去除上清，更换药物浓度为50μM的培养基继续培养，设置GCRV感染对照组和50μM浓度的槲皮素给药组，分别取24、48、72、96h的样品进行定量和WB检测，结果如图3所示。
由图可知，与感染对照组相比，50μM槲皮素处理组在各个时间点病毒滴度都要显著低于感染对照组，说明浓度为50μM的槲皮素抗GCRV效果好。
综上，本发明通过细胞实验首次发现槲皮素可以抑制GCRV病毒，且抗GCRV病毒效果良好，因其原料成本低廉，绿色安全且效果良好，符合当前水产养殖绿色鱼药对安全、环保的要求，将其开发为抗GCRV的水产养殖用绿色药物。
上述对实施例的描述是为了便于该技术领域的普通技术人员能理解和使用本发明。熟悉本领域技术人员显然可以容易的对这些实施例做出各种修改，并把在此说明的一般原理应用到其他实施例中，而不必经过创造性的劳动。因此，本发明不限于上述实施例。本领域技术人员根据本发明的原理，不脱离本发明的范畴所做出的改进和修改都应该在本发明的保护范围之内。
Claims (2)
1.槲皮素在制备抗草鱼呼肠孤病毒药物中的用途，所述槲皮素作为抗病毒活性成分用于制备抗草鱼呼肠孤病毒药物，其应用剂量为0.1-100μM/L；
还包括药学上可接受的辅料；
所述抗草鱼呼肠孤病毒药物的剂型包括片剂、粉剂、颗粒剂、胶囊或缓释剂，给药方式为拌饲投喂。
2.根据权利要求1所述的用途，其特征在于，所述槲皮素的应用剂量为25-50μM/L。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010965543.2A CN111973587B (zh) | 2020-09-15 | 2020-09-15 | 槲皮素在制备抗草鱼呼肠孤病毒药物中的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010965543.2A CN111973587B (zh) | 2020-09-15 | 2020-09-15 | 槲皮素在制备抗草鱼呼肠孤病毒药物中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111973587A CN111973587A (zh) | 2020-11-24 |
| CN111973587B true CN111973587B (zh) | 2022-11-04 |
Family
ID=73449778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010965543.2A Active CN111973587B (zh) | 2020-09-15 | 2020-09-15 | 槲皮素在制备抗草鱼呼肠孤病毒药物中的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111973587B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115040537B (zh) * | 2022-06-22 | 2023-09-01 | 中国科学院水生生物研究所 | 锰离子在防治水生病毒感染中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103756973A (zh) * | 2013-12-26 | 2014-04-30 | 中国水产科学研究院珠江水产研究所 | 一种草鱼呼肠孤病毒的间接elisa检测试剂盒 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4298043B2 (ja) * | 1999-03-18 | 2009-07-15 | オリジナル・イメージ株式会社 | 養魚用飼料 |
| US20050181082A1 (en) * | 2002-05-21 | 2005-08-18 | Fumiyuki Isami | Morinda citrifolla based antifungal formulations and methods |
| KR100720151B1 (ko) * | 2005-12-13 | 2007-05-18 | 한국생명공학연구원 | 항바이러스 활성을 갖는 플라보노이드 화합물 |
| CN102935166A (zh) * | 2012-11-12 | 2013-02-20 | 何聪 | 一种中草药复方鱼药 |
| KR101531937B1 (ko) * | 2013-08-01 | 2015-07-06 | 한국기초과학지원연구원 | 퀘르세틴을 유효성분으로 하는 어류의 항바이러스 조성물 |
-
2020
- 2020-09-15 CN CN202010965543.2A patent/CN111973587B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103756973A (zh) * | 2013-12-26 | 2014-04-30 | 中国水产科学研究院珠江水产研究所 | 一种草鱼呼肠孤病毒的间接elisa检测试剂盒 |
Non-Patent Citations (1)
| Title |
|---|
| 槲皮素的研究进展;于夏等;《河南职工医学院学报》;20111231;第391-392页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111973587A (zh) | 2020-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111588721B (zh) | 化合物zl0580用于制备预防或治疗非洲猪瘟药物的新用途 | |
| Hu et al. | Synthesis and antiviral activity of a new arctigenin derivative against IHNV in vitro and in vivo | |
| Liu et al. | Antiviral abilities of Curcuma kwangsiensis ingredients against grouper iridoviral infection in vitro and in vivo | |
| CN102274314A (zh) | 常青球虫散及其制备方法 | |
| CN113082049A (zh) | 碘化钾或含有碘化钾的组合物用于预防或治疗非洲猪瘟的新用途 | |
| Ji et al. | Effect of berberine hydrochloride on grass carp Ctenopharyngodon idella serum bactericidal activity against Edwardsiella ictaluri | |
| CN111973587B (zh) | 槲皮素在制备抗草鱼呼肠孤病毒药物中的用途 | |
| KR101653884B1 (ko) | 항 콕사키바이러스 활성을 갖는 오리방풀 유래 화합물 | |
| WO2002102308A2 (en) | Pharmaceutical composition for the treatment of viral infection | |
| CN108578399B (zh) | 氨基酸酯化合物在制备抗cvb3病毒药物中的应用 | |
| CN115770245A (zh) | 双苄基异喹啉生物碱在制备防治非洲猪瘟病毒药物中的应用 | |
| CN113521262B (zh) | 一种具有抗炎效果的溶菌酶制剂 | |
| CN111686107B (zh) | 化合物plx51107用于制备预防或治疗非洲猪瘟药物的新用途 | |
| CN111588725B (zh) | 化合物arv-825用于制备预防或治疗非洲猪瘟药物的新用途 | |
| CN111658654A (zh) | 化合物jq-1用于预防或治疗非洲猪瘟的新用途 | |
| CN106957826B (zh) | 一种病毒灭活剂及其应用 | |
| CN104758340B (zh) | 一种忍冬叶中咖啡酰奎宁酸类提取物及其制备方法和用途 | |
| CN101502536B (zh) | 香柏总黄酮及其制备方法与医药用途 | |
| CN116650577B (zh) | 一种锦灯笼提取物在抗鸡传染性支气管炎病毒中的应用 | |
| CN111686114B (zh) | 化合物i-bet-762用于制备预防或治疗非洲猪瘟药物的新用途 | |
| Yang et al. | Natural product honokiol exhibits antiviral effects against Micropterus salmoides rhabdovirus (MSRV) both in vitro and in vivo | |
| WO2018030857A1 (ko) | 삼칠근 추출물을 함유하는 항바이러스용 조성물 | |
| CN105770054A (zh) | 用于防治鸡球虫病的药物组合物、添加剂和饲料 | |
| CN108272788B (zh) | 葛根素在制备防治猪病毒感染的药物中的用途、防治猪病毒感染的药物及猪饲料添加剂 | |
| CN113995748B (zh) | 鞣花酸在制备治疗或预防猪病毒性腹泻药物或饲料添加剂中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240301 Address after: 044102 North of Nanda Village Committee, Linjin Town, Linyi County, Yuncheng City, Shanxi Province Patentee after: Yuncheng Yubo Biotechnology Co.,Ltd. Country or region after: China Address before: 201306, No. 999, Huan Cheng Road, Pudong New Area, Shanghai Patentee before: SHANGHAI OCEAN University Country or region before: China |